The estimated Net Worth of Stephen Michael Moore is at least 495 千$ dollars as of 17 June 2024. Mr. Moore owns over 1,585 units of Personalis Inc stock worth over 411,032$ and over the last 3 years he sold PSNL stock worth over 84,157$. In addition, he makes 0$ as General Counsel at Personalis Inc.
Stephen has made over 13 trades of the Personalis Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,585 units of PSNL stock worth 2,045$ on 17 June 2024.
The largest trade he's ever made was selling 5,733 units of Personalis Inc stock on 2 May 2022 worth over 31,703$. On average, Stephen trades about 1,861 units every 46 days since 2022. As of 17 June 2024 he still owns at least 69,081 units of Personalis Inc stock.
You can see the complete history of Mr. Moore stock trades at the bottom of the page.
Stephen Moore serves as General Counsel of the Company. He joins Personalis after a decade at Pacific Biosciences (NASDAQ: PACB), where he served as General Counsel. Prior to Pacific Biosciences, Mr. Moore was General Counsel at Navigenics, a consumer genomics company that was later acquired by Life Technologies (now part of Thermo Fisher Scientific). Prior to Navigenics, he worked for over eight years at DNA microarray pioneer Affymetrix (which was also later acquired by Thermo Fisher Scientific), where he was most recently an Associate General Counsel. Mr. Moore holds a Bachelor of Arts degree in Political Science from San Jose State University, and a law degree from the University of California, Davis.
Stephen's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 5 years, insiders at Personalis Inc have traded over 56,423,548$ worth of Personalis Inc stock and bought 5,708,990 units worth 54,066,334$ . The most active insiders traders include Llp Abingworth、Paul Ricci、Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of 410,996$. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth 17,745,000$.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: